Deutsche Bank Analysts Give Pfizer (PFE) a $38.00 Price Target

Pfizer (NYSE:PFE) has been given a $38.00 price target by analysts at Deutsche Bank in a research note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank’s price target suggests a potential upside of 6.65% from the stock’s previous close.

A number of other equities research analysts have also weighed in on PFE. Berenberg Bank restated a “hold” rating and issued a $36.00 target price (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Cowen set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Jefferies Group set a $38.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Saturday, November 25th. Finally, Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, September 19th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $38.66.

Shares of Pfizer (PFE) opened at $35.63 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The firm has a market cap of $214,943.11, a PE ratio of 14.42, a P/E/G ratio of 2.54 and a beta of 1.01.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the prior year, the business posted $0.61 EPS. The firm’s revenue was up .9% compared to the same quarter last year. analysts expect that Pfizer will post 2.59 earnings per share for the current fiscal year.

In other news, insider Sally Susman sold 38,230 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 60,280 shares of company stock valued at $2,118,988. Company insiders own 0.06% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in PFE. Shine Investment Advisory Services Inc. bought a new position in Pfizer in the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer in the 2nd quarter worth approximately $103,000. D. Scott Neal Inc. boosted its holdings in Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer in the 1st quarter worth approximately $121,000. Finally, Herndon Capital Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $120,000. 69.89% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Deutsche Bank Analysts Give Pfizer (PFE) a $38.00 Price Target” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/06/deutsche-bank-analysts-give-pfizer-pfe-a-38-00-price-target.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply